Abstract
E1A is a multifunctional adenoviral protein expressed early after infection that interferes with numerous important regulatory processes by interaction with host cell proteins or direct transcriptional activation of target genes. Although, initially identified as the adenoviral component that can cause malignant conversion of rodent cells, remarkable tumorsuppressive effects of E1A on various types of human cancer cells were observed. Gene therapeutic approaches with E1A are currently evaluated in animal models and early clinical studies. Therapeutic applications of E1A are covered by a series of patents which include the description of small variants (mini-E1A) that can be used for tumor suppression and E1A gene transfer in combination with conventional chemotherapy. In this mini review, we provide an introduction to E1A functions, summarize relevant patents, and discuss potential clinical applications of E1A gene transfer on basis of recent results of clinical and preclinical investigations.
Keywords: Gene therapy, adenovirus, E1A, breast cancer, ovarian cancer, head and neck cancer, apoptosis, HER-2/neu
Recent Patents on Anti-Cancer Drug Discovery
Title: Therapeutic Transfer of DNA Encoding Adenoviral E1A
Volume: 2 Issue: 1
Author(s): Helmut Deissler and Bertram Opalka
Affiliation:
Keywords: Gene therapy, adenovirus, E1A, breast cancer, ovarian cancer, head and neck cancer, apoptosis, HER-2/neu
Abstract: E1A is a multifunctional adenoviral protein expressed early after infection that interferes with numerous important regulatory processes by interaction with host cell proteins or direct transcriptional activation of target genes. Although, initially identified as the adenoviral component that can cause malignant conversion of rodent cells, remarkable tumorsuppressive effects of E1A on various types of human cancer cells were observed. Gene therapeutic approaches with E1A are currently evaluated in animal models and early clinical studies. Therapeutic applications of E1A are covered by a series of patents which include the description of small variants (mini-E1A) that can be used for tumor suppression and E1A gene transfer in combination with conventional chemotherapy. In this mini review, we provide an introduction to E1A functions, summarize relevant patents, and discuss potential clinical applications of E1A gene transfer on basis of recent results of clinical and preclinical investigations.
Export Options
About this article
Cite this article as:
Deissler Helmut and Opalka Bertram, Therapeutic Transfer of DNA Encoding Adenoviral E1A, Recent Patents on Anti-Cancer Drug Discovery 2007; 2 (1) . https://dx.doi.org/10.2174/157489207779561471
DOI https://dx.doi.org/10.2174/157489207779561471 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Development of Ribonucleotide Reductase Inhibitors: A Review on Structure Activity Relationships
Mini-Reviews in Medicinal Chemistry The Role of Image Guided Radiotherapy in the Treatment of Soft Tissue Sarcoma
Current Cancer Therapy Reviews The Complexity of DEK Signaling in Cancer Progression
Current Cancer Drug Targets Molecular Pathways Involved in Apoptotic Cell Death in the Injured Cochlea: Cues to Novel Therapeutic Strategies
Current Pharmaceutical Design Cytoskeletal Alterations that Confer Resistance to Anti-tubulin Chemotherapeutics
Anti-Cancer Agents in Medicinal Chemistry Salinomycin: A Novel Anti-Cancer Agent with Known Anti-Coccidial Activities
Current Medicinal Chemistry Histone Modifications as Molecular Targets in Nasopharyngeal Cancer
Current Medicinal Chemistry Clinical Development of Experimental Virus-Mediated Gene Therapy for Malignant Glioma
Anti-Cancer Agents in Medicinal Chemistry Predicting Targeted Polypharmacology for Drug Repositioning and Multi- Target Drug Discovery
Current Medicinal Chemistry Small Molecular Inhibitors Targeting Chromatin Regulating Proteins for Cancer
Current Protein & Peptide Science Bortezomib: A New Pro-Apoptotic Agent in Cancer Treatment
Current Cancer Drug Targets STAT 3 as a Target for Cancer Drug Discovery
Current Medicinal Chemistry Amplification of Anticancer Drug-Induced DNA Damage and Apoptosis by DNA-Binding Compounds
Current Medicinal Chemistry - Anti-Cancer Agents The Effect of Pyrroloquinoline Quinone on Apoptosis and Autophagy in Traumatic Brain Injury
CNS & Neurological Disorders - Drug Targets Reducing radiation in chronic total occlusion percutaneous coronary interventions
Current Cardiology Reviews Protective Effect of Anthocyanins on Radiation-induced Hippocampal Injury through Activation of SIRT3
Current Pharmaceutical Design How to Achieve Near Zero Fluoroscopy During Radiofrequency Ablation of Atrial Fibrillation: A Strategy Used at Two Centers
Current Cardiology Reviews DNA Methylation Based Biomarkers in Non-Invasive Cancer Screening
Current Molecular Medicine Semaphorins at the Interface of Development and Cancer
Current Drug Targets Receptor Tyrosine Kinases: The Main Targets for New Anticancer Therapy
Current Drug Targets